Trial Profile
Everolimus and Mycophenolate Sodium as GvHD Prophylaxis in Allogeneic Stem Cell Transplantation
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Everolimus (Primary) ; Mycophenolate sodium (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 01 Aug 2021 Status changed from recruiting to discontinued, as per published in the Annals of Hematology
- 01 Aug 2021 The study protocol has been amended after 24 patients with alemtuzumab in the conditioning regimen due to high rates of severe acute and chronic GVHD rates
- 01 Aug 2021 Results assessing combination of everolimus and mycophenolate mofetil as a GVHD prophylaxis, published in the Annals of Hematology